BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
315.32 USD
-6.74 (-2.09%)
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year BIO was profitable.
- In the past year BIO had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
- In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
- BIO has a Return On Assets (-6.97%) which is in line with its industry peers.
- BIO has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
- The Return On Invested Capital of BIO (2.26%) is better than 61.40% of its industry peers.
- BIO had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO has a Operating Margin of 10.27%. This is in the better half of the industry: BIO outperforms 70.18% of its industry peers.
- In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
- Looking at the Gross Margin, with a value of 52.42%, BIO is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
- BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- BIO has less shares outstanding than it did 1 year ago.
- BIO has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.48 indicates that BIO is not in any danger for bankruptcy at the moment.
- BIO has a Altman-Z score of 3.48. This is in the better half of the industry: BIO outperforms 66.67% of its industry peers.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- BIO has a Debt to FCF ratio of 3.57. This is in the better half of the industry: BIO outperforms 77.19% of its industry peers.
- BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.48 |
ROIC/WACC0.21
WACC10.63%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO's Current ratio of 5.44 is amongst the best of the industry. BIO outperforms 85.96% of its industry peers.
- BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO has a better Quick ratio (3.94) than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -1.90% in the last year.
- BIO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
- Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
- BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
- The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 30.58, the valuation of BIO can be described as expensive.
- 71.93% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
- BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
- BIO is valuated quite expensively with a Price/Forward Earnings ratio of 30.61.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 70.18% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.31. BIO is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.58 | ||
| Fwd PE | 30.61 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.26 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.9
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
5. Dividend
5.1 Amount
- BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO (1/16/2026, 3:33:43 PM)
315.32
-6.74 (-2.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners92.92%
Inst Owner Change0.07%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.50B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (14.84%)
Short Float %4.91%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.58%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.14%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.58 | ||
| Fwd PE | 30.61 | ||
| P/S | 3.33 | ||
| P/FCF | 25.26 | ||
| P/OCF | 17.3 | ||
| P/B | 1.26 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.27%
EPS(NY)10.3
Fwd EY3.27%
FCF(TTM)12.48
FCFY3.96%
OCF(TTM)18.22
OCFY5.78%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.9
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.48 |
F-Score5
WACC10.63%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y14.51%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.19% in the next year.